^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:HER2 Negative Breast Cancer
    Drug:TQB3616 (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

    Excerpt:
    ...- 3 participants with estrogen receptor-positive, HER2-Negative Advanced Breast Cancer were identified by pathological testing....
    Trial ID:
    NCT05375461
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Breast Cancer (Dove Med Press)
    Title:

    The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models

    Published date:
    12/08/2023
    Excerpt:
    TQB3616 showed a remarkable inhibitory effect on the proliferation of hormone receptor-positive breast cancer cells in vitro. In addition, TQB3616 combined with endocrine therapy or Human Epidermal Growth Factor Receptor 2 (HER2) targeted therapy showed significant synergistic antitumor activity in estrogen receptor (ER)-positive/HER2-negative or HER2-positive breast cancer.
    Secondary therapy:
    HER2 inhibitor; Hormone Therapy
    DOI:
    https://doi.org/10.2147/BCTT.S434973